Dysregulation of the TSC-mTOR pathway in human disease

K Inoki, MN Corradetti, KL Guan - Nature genetics, 2005 - nature.com
The mammalian target of rapamycin (mTOR) has a central role in the regulation of cell
growth. mTOR receives input from multiple signaling pathways, including growth factors and …

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

MN Corradetti, K Inoki, N Bardeesy… - Genes & …, 2004 - genesdev.cshlp.org
Tuberous sclerosis complex (TSC) and Peutz-Jeghers syndrome (PJS) are dominantly inherited
benign tumor syndromes that share striking histopathological similarities. Here we show …

TSC2: filling the GAP in the mTOR signaling pathway

Y Li, MN Corradetti, K Inoki, KL Guan - Trends in biochemical sciences, 2004 - cell.com
The tumor-suppressor proteins TSC1 and TSC2 are associated with an autosomal dominant
disorder known as tuberous sclerosis complex (TSC). TSC1 and TSC2 function as a …

[HTML][HTML] The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway

MN Corradetti, K Inoki, KL Guan - Journal of Biological Chemistry, 2005 - ASBMB
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays an
essential role in cell growth control. mTOR stimulates cell growth by phosphorylating p70 …

Central-airway necrosis after stereotactic body-radiation therapy

MN Corradetti, AR Haas… - New England journal of …, 2012 - Mass Medical Soc
Central-Airway Necrosis after Stereotactic Body-Radiation Therapy | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Radiogenomic analysis of locally advanced lung cancer based on CT imaging and intratreatment changes in cell-free DNA

KJ Lafata, MN Corradetti, J Gao, CD Jacobs… - Radiology: Imaging …, 2021 - pubs.rsna.org
The radiologic appearance of locally advanced lung cancer may be linked to molecular
changes of the disease during treatment, but characteristics of this phenomenon are poorly …

Five-year long-term outcomes of stereotactic body radiation therapy for operable versus medically inoperable stage i non–small-cell lung cancer: analysis by …

…, MA Frick, EP Xanthopoulos, MN Corradetti… - Clinical Lung Cancer, 2019 - Elsevier
Background Stereotactic body radiation therapy (SBRT) is standard for medically inoperable
stage I non–small-cell lung cancer (NSCLC) and is emerging as a surgical alternative in …

Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer

…, L Li, AJ Munaco, A Sreekumar, MN Corradetti… - Cancer research, 2005 - AACR
Huntingtin-interacting protein 1 (HIP1) is frequently overexpressed in prostate cancer. HIP1
is a clathrin-binding protein involved in growth factor receptor trafficking that transforms …

[HTML][HTML] Dynamic simulation of motion effects in IMAT lung SBRT

W Zou, L Yin, J Shen, MN Corradetti, M Kirk… - Radiation …, 2014 - Springer
Background Intensity modulated arc therapy (IMAT) has been widely adopted for Stereotactic
Body Radiotherapy (SBRT) for lung cancer. While treatment dose is optimized and …

Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications

MJ Eblan, MN Corradetti, JN Lukens… - International Journal of …, 2013 - Elsevier
PURPOSE: Data are limited on the clinical significance of brachial plexopathy in patients
with apical non-small cell lung cancers (NSCLC) treated with definitive radiation therapy. We …